The efficacy of omalizumab therapy in chronic spontaneous urticaria: A retrospective analysis Kronik spontan ürtikerde omalizumab tedavisinin etkinligi: Retrospektif degerlendirilme

TÜRKMEN M., Çoban M., Dogan S., Uygur F., Soylu I. H.

Turkderm Turkish Archives of Dermatology and Venereology, cilt.53, sa.2, ss.65-67, 2019 (Scopus, TRDizin)

Özet

Background and Design: Omalizumab is recombinant humanized monoclonal antibody that binds to immunoglobulin E (IgE). It inhibits the activation of IgE by binding to the effector cell, thereby inhibiting the release of cellular mediators. Omalizumab is indicated in H1- antihistamine-resistant chronic spontaneous urticaria (CSU) cases and data on successful use in CSU is increasing. The aim of this study was to evaluate the efficacy and possible side effects of omalizumab, the period from the discontinuation of treatment to the relapse of symptoms, and the clinical and demographic characteristics of patients with refractory CSU. Materials and Methods: We retrospectively evaluated the data of 130 patients with refractory CSU who received subcutaneous 300 mg/ month omalizumab therapy in our clinic. Results: Complete remission was achieved in 77.8% of the patients. Of the 80 patients who discontinued therapy due to remission, 55% had relapses within 2 months to 1 year. It was observed that the efficacy of the drug was not lost and the efficacy did not change in the patients who started the treatment again. Six percent of the patients did not respond to treatment. Clinical improvement was found to be independent of age, gender, presence of angioedema, high thyroid autoantibody levels and disease duration. No serious side effects were found in the patients. Conclusion: In patients with refractory CSU, omalizumab is an effective and safe treatment option.